Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
Vertex Pharmaceuticals(VRTX) stock is priced at $425.60, giving the company a market capitalization of 107.98B. It carries a P/E multiple of 30.56.
During the trading session on 2025-12-01, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $434.00 and a low of $423.46. At a current price of $425.60, the stock is +0.5% higher than the low and still -1.9% under the high.
Trading volume for Vertex Pharmaceuticals(VRTX) stock has reached 995.74K, versus its average volume of 1.4M.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
VRTX News
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twi...
Vertex Pharmaceuticals recently announced updated data from its RUBY-3 trial, showing that povetacicept led to substantial reductions in proteinuria and stabili...
Image source: The Motley Fool. Monday, November 3, 2025 at 10:06 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Reshma Kewalramani Chief Operating Officer...
Analyst ratings
58%
of 36 ratingsMore VRTX News
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth I...
Ever wondered if Vertex Pharmaceuticals is a hidden gem or if its current share price leaves little room for upside? Let's dive in together and see what the num...
Prediction: Vertex will be much larger by the end of the decade. A lot can change in five years. Take Vertex Pharmaceuticals (VRTX +0.57%), for example. In lat...
Vertex Pharmaceuticals (VRTX) halted standalone development of its pain drug VX-993 after disappointing results in a mid-stage clinical trial. This update, alon...